A narrative review integrated neurotransmitter and basal-ganglia hypotheses. Its framework did not establish that a lorazepam response proves one unique circuit defect.
The proposed model
The review brought together clinical, imaging, and preclinical studies concerning GABA, dopamine, glutamate, serotonin, and acetylcholine. It proposed that disrupted indirect-pathway control helps explain motor and behavioral features of catatonia.
Benzodiazepine treatment was discussed within that model alongside preliminary evidence concerning other targets.
Integration is not direct confirmation
A narrative synthesis can connect plausible observations without directly testing the entire causal chain in one experiment. Different conditions causing catatonia may not share identical mechanisms or medication responses.
The article does not validate a circuit-specific biomarker or establish the sensitivity and specificity of a benzodiazepine challenge. For interpretation, distinguish a clinical syndrome, response to treatment, and a proposed neural explanation. The review supports mechanistic questions, but cannot establish an individual diagnosis or rule out medical causes from a favorable response alone.
Source paper
Original analysis of the supplied journal article, identified as PMC12302819.
Leave a Reply